ישראל - עברית - Ministry of Health

zoetis israel holding b.v., israel - cefovicin as sodium salt - אבקה וממס להכנת תמיסה להזרקה - cefovicin as sodium salt 80 mg/dose - dogs : for the treatment of skin and soft tissue infections including pyoderma wounds and abscesses associated with staphylococcus intermedius beta-haemolytic streptococci escherichia coli and/or pasteurella multocida. for the treatment of urinary tract infections associated with escherichia coli and/or proteus spp.as adjunctive treatment to mechanical or surgical periodontal therapy of severe infections of the gingival and periodontal tissues associated with porphyromonas spp. and prevotella spp. cats : for the treatment of skin and soft tissue abscesses and wounds associated with pasteurella multocida fusobacterium spp. bacteroides spp. prevotella oralis beta-haemolytic streptococci and/or staphylococcus intermedius. for the treatment of urinary tract infections associated with escherichia coli.

ישראל - עברית - Ministry of Health

עינת מדיקל סוכנויות בע"מ -

ישראל - עברית - Ministry of Health

עינת מדיקל סוכנויות בע"מ - צוות טכני - מוצרים לאבחון טיב הסטריליזציה

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - cefovicin as sodium salt 80 mg/dose - powder for solution for injection - dogs : for the treatment of skin and soft tissue infections including pyoderma wounds and abscesses associated with staphylococcus intermedius beta-haemolytic streptococci escherichia coli and/or pasteurella multocida. for the treatment of urinary tract infections associated with escherichia coli and/or proteus spp. as adjunctive treatment to mechanical or surgical periodontal therapy of severe infections of the gingival and periodontal tissues associated with porphyromonas spp. and prevotella spp.cats : for the treatment of skin and soft tissue abscesses and wounds associated with pasteurella multocida fusobacterium spp. bacteroides spp. prevotella oralis beta-haemolytic streptococci and/or staphylococcus intermedius. for the treatment of urinary tract infections associated with escherichia coli.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - אבקה להכנת תרחיף - cefalexin as monohydrate 250 mg / 5 ml - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 250 mg - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

ישראל - עברית - Ministry of Health

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 500 mg - cefalexin - cefalexin - treatment of infections caused by cephalexin susceptible microorganisms.

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob